ACXP stock forecast, quote, news & analysis
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections... Show more
Why Acurx Pharmaceuticals (ACXP) Stock Is Down -18.75% in the Last 30 Days
Key Takeaways
- Acurx Pharmaceuticals (ACXP) fell roughly 18.75% over the 30 days ending November 10, 2026, sliding from a closing price near $1.28 to about $1.04.
- The decline is part of a longer downtrend, with shares down approximately 29% over the trailing quarter from a level near $1.47.
- As a pre-revenue, clinical-stage antibiotic developer, Acurx remains sensitive to financing, dilution, and clinical-execution risks that weigh on micro-cap biotech valuations.
- The company's lead candidate, ibezapolstat, is advancing toward Phase 3 development for C. difficile infection, with enrollment underway in a multiply-recurrent CDI pilot trial.
- Investors are closely watching the company's third-quarter 2026 financial results, which were scheduled to be discussed on November 12, 2026.
- For additional context on valuation and expectations, explore Price Targets, Earnings, and Forecast pages for ACXP.
- To see how AI-driven trading systems are approaching similar setups, visit the Trending AI Robots section.
Acurx Pharmaceuticals (ACXP) Company Overview and Market Position
Acurx Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing a new class of small-molecule antibiotics targeting serious, life-threatening Gram-positive bacterial infections. Its core scientific platform centers on Gram-Positive Selective Spectrum (GPSS®) compounds that inhibit DNA polymerase IIIC, an enzyme critical to Gram-positive bacterial DNA replication.
The company's lead candidate, ibezapolstat, is an orally administered treatment for C. difficile infection (CDI) and is positioned as Phase 3-ready. The U.S. Food and Drug Administration granted ibezapolstat Qualified Infectious Disease Product (QIDP) designation in 2018 and Fast Track designation in 2019. Acurx's broader preclinical pipeline targets pathogens including MRSA, vancomycin-resistant Enterococcus, drug-resistant Streptococcus pneumoniae, and Bacillus anthracis. As a pre-revenue company, Acurx is followed primarily for its clinical milestones, regulatory pathway, and ability to fund development rather than for current earnings.
Acurx Pharmaceuticals (ACXP) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ACXP declined from a closing price near $1.28 on October 12, 2026, to approximately $1.04 on November 10, 2026, a move of roughly -18.75%. The descent was largely steady rather than driven by a single event, punctuated by a sharp intraday drop on November 5, 2026, when shares touched a 52-week low around $0.9457 before stabilizing.
The quarterly picture is similarly weak. Compared with a level near $1.47 in mid-August 2026, the stock is down roughly 29%, extending a decline from a 52-week range that peaked above $7.50. With a market capitalization in the single-digit millions and modest average daily trading volume, ACXP experiences limited liquidity, which can amplify both up and down moves.
What Drove ACXP Stock Price in the Last 30 Days
The 30-day decline reflected a combination of company-specific and market-structure factors. As a pre-revenue clinical-stage developer, Acurx generates no product sales, leaving the shares dependent on clinical catalysts and capital availability. The period lacked a single transformational data readout, and the stock continued a longer pattern of downward pressure amid thin trading liquidity.
Company updates during the window were largely operational rather than value-creating in the near term. Acurx announced it would report third-quarter 2026 results on November 12, 2026, and highlighted enrollment progress in its open-label, 20-patient pilot trial for multiply-recurrent C. difficile infection, with the first patient enrolled in September 2026. The company also published data supporting a potential microbiome-sparing class effect for its DNA pol IIIC inhibitor pipeline. While clinically meaningful, these updates did not offset concerns typical of micro-cap biotechs, including funding needs and potential dilution, and shares broke to a new 52-week low before recovering modestly.
What Drove ACXP Stock Performance Over the Last Quarter
The quarterly trend reflects a sustained de-rating from a stock that traded above $7 within the past year to roughly $1.04. Over the trailing three months, ACXP gave back about 29%, with intermittent spikes but an overall downward bias. The company's second-quarter 2026 report, released in August 2026, showed a loss per share that came in wider than consensus expectations, reinforcing the challenge of valuing a company with no revenue and ongoing clinical spending.
At the same time, Acurx advanced its regulatory roadmap, including final FDA agreement on key design elements for an ibezapolstat pivotal Phase 3 trial in acute CDI and the launch of the recurrent-CDI pilot study. These milestones establish a clearer path to late-stage development but also imply significant future capital requirements, a dynamic that has kept pressure on the stock.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots from a broader platform that offers hundreds of automated systems across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, with each bot differing in strategy, timeframe, and performance metrics. The page is designed to help traders compare approaches and identify automated strategies that match their own objectives and risk tolerance. Investors interested in data-driven market signals may find the section a useful starting point for exploring how algorithmic tools interpret changing conditions.
ACXP Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst for ACXP is its third-quarter 2026 financial update, which was scheduled to be discussed on November 12, 2026. Analysts' consensus pointed to a narrower loss than the prior-year quarter, but cash position, runway, and any commentary on financing plans will likely matter as much as the headline EPS figure for a pre-revenue developer.
Beyond earnings, investors should monitor enrollment and data timing for the multiply-recurrent CDI pilot trial, progress toward initiating international Phase 3 trials in acute CDI, and any updates on the regulatory pathway for ibezapolstat. Broader factors such as risk appetite for micro-cap biotechs, access to capital markets, and antibiotic-sector sentiment could also influence trading. As with any clinical-stage company, the investment case carries substantial uncertainty, and outcomes depend heavily on trial results and funding execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ACXP in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
ACXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 43 of 49 cases where ACXP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACXP's RSI Indicator exited the oversold zone, 36 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 73 cases where ACXP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for ACXP just turned positive on November 09, 2026. Looking at past instances where ACXP's MACD turned positive, the stock continued to rise in 26 of 39 cases over the following month. The odds of a continued upward trend are 67%.
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACXP advanced for three days, in 171 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ACXP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.559) is normal, around the industry mean (3.498). P/E Ratio (-0.434) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ACXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology